Astellas Pharma Inc. (ALPMY)
OTCMKTS
· Delayed Price · Currency is USD
9.73
+0.06 (0.62%)
Feb 21, 2025, 3:59 PM EST
Astellas Pharma Employees
Astellas Pharma had 14,754 employees as of March 31, 2024. The number of employees increased by 270 or 1.86% compared to the previous year.
Employees
14,754
Change (1Y)
270
Growth (1Y)
1.86%
Revenue / Employee
$805,144
Profits / Employee
-$24,757
Market Cap
17.55B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| Endo Inc. | 2,931 |
| Elite Pharmaceuticals | 64 |
| Glass House Brands | 413 |
| CytoDyn | 9 |
| Northwest Biotherapeutics | 25 |
| Silence Therapeutics | 109 |
| SANUWAVE Health | 31 |
Astellas Pharma News
- 10 days ago - U.S. FDA Approves Expanded Label for Astellas' IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy - PRNewsWire
- 11 days ago - Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo - Benzinga
- 12 days ago - Pfizer and Astellas' PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC) - Benzinga
- 14 days ago - Astellas Pharma Inc. (ALPMF) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 14 days ago - Astellas Pharma Inc. 2024 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 17 days ago - Astellas Submits New Drug Application for Conditional Approval of Avacincaptad Pegol for Geographic Atrophy in Japan - PRNewsWire
- 18 days ago - Astellas Pharma Non-GAAP EPS of ¥124.60, revenue of ¥1453.03B; updates FY outlook - Seeking Alpha
- 18 days ago - Astellas Makes Announcement about Management Structure - PRNewsWire